buy first commerci quarter ayvakit
launch mileston remain
messag report result includ ayvakit first partial
launch quarter clinic mileston line investor expect despit
uncertainti modest impact busi oper compani remain
track key mileston data readout throughout ayvakit system
mastocytosi pralsetinib ret tumor trial initi healthi volunt
preclin data next-gener egfr inhibitor featur previous
 day link updat estim account result maintain buy
pt
first partial quarter sale ayvakit initi approv pdgfra gist link
report ayvakit sale vs consensu first quarter
commercial-stag compani management note difficulti anticip launch
trajectori given on-going uncertainti major sale came new patient demand
small amount due convers compassion use commerci suppli
insignific contribut inventori patient stock regard potenti
off-label use given nccn guidelin support kit gist management note
code distinguish variou mutant could pull apart gist patient
mutat statu precis addit current see gross-to-net
price adjust could chang go-forward basi well fluctuat
signific patient assist program util throughout quarter
modest impact date shift work-from-hom
work ensur clinic trial continu see impact note
compani shift commerci medic affair field activ virtual format
expect pend favor evolut pandem re-initi in-person engag
local region appropri also suffici clinic commerci suppli
across portfolio
multipl upcom clinic data updat across portfolio see
planner eaaci eha confer featur updat data
ret inhibitor pralsetinib recent read top line nsclc link mtc link
data recal recent kol feedback see oncolog day nsclc panel takeaway
highlight pralsetinib respons deepen higher cr rate could indic
possibl slightli potent drug rel competitor selpercatinib eaaci
featur addit data part ayvakit phase ii pioneer trial
previous read posit data aaaai confer link select
mg updat ayvakit advanc sm data phase explor
present eha
compani remain track head toward pipelin mileston
throughout expect submit nda pralsetinib mtc
well initi patient screen registr part pioneer
initi phase studi next-gener kit/pdgfra inhibitor ind clear
healthi volunt june top line result phase explor phase
ii pathfind trial consist potenti registration-en data avapritinib
advanc sm remain track nda submiss also track initi
preclin data next-gener egfr inhibitor post-tagrisso azn lung cancer
set also expect
updat model account result maintain buy pt end
quarter cash invest management believ provid runway
modestli adjust oper expens forecast account result
page analyst certif import disclosur
valuat valu per share use dcf base valuat method valuat includ
probability-adjust cash flow deriv compani pipelin includ avapritinib use discount rate
termin growth rate appli termin year post-assum gener entri lead pipelin candid
risk risk valuat includ regulatori commerci setback potenti emerg
new competitor lower product sale expect
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
